Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors.

[1]  Sumudu P Leelananda,et al.  Computational methods in drug discovery , 2016, Beilstein journal of organic chemistry.

[2]  E. Saleh,et al.  In-silico screening for DNA-dependent protein kinase (DNA-PK) inhibitors: Combined homology modeling, docking, molecular dynamic study followed by biological investigation. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Theodora Katsila,et al.  Computational approaches in target identification and drug discovery , 2016, Computational and structural biotechnology journal.

[4]  Walter Thiel,et al.  Semiempirical Quantum-Chemical Orthogonalization-Corrected Methods: Theory, Implementation, and Parameters , 2016, Journal of chemical theory and computation.

[5]  Hany E. A. Ahmed,et al.  Molecular pharmacophore selectivity studies, virtual screening, and in silico ADMET analysis of GPCR antagonists , 2015, Medicinal Chemistry Research.

[6]  Saleh K. Ihmaid,et al.  Synthesis, toxicity and chemo-sensitization of HeLa cells to etoposide, of some 2-methyl amino acid ester-substituted-1,3-benzoxazines , 2015, Medicinal Chemistry Research.

[7]  J. Al-Rawi,et al.  Dual and/or selective DNA-PK, PI3K inhibition and isoform selectivity of some new and known 2-amino-substituted-1,3-benzoxazines and substituted-1,3-naphthoxazines , 2014, Medicinal Chemistry Research.

[8]  Saleh K. Ihmaid,et al.  Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair , 2014, Investigational New Drugs.

[9]  Edward W. Lowe,et al.  Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.

[10]  James J. P. Stewart,et al.  Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters , 2012, Journal of Molecular Modeling.

[11]  Murray N. Robertson,et al.  Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. , 2012, European journal of medicinal chemistry.

[12]  R. Mirzayans,et al.  New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy , 2012, Journal of biomedicine & biotechnology.

[13]  Murray N. Robertson,et al.  Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines. , 2011, Bioorganic & medicinal chemistry.

[14]  Jie Fu,et al.  Synthesis, structure and structure-activity relationship analysis of caffeic acid amides as potential antimicrobials. , 2010, European journal of medicinal chemistry.

[15]  K. Aziz,et al.  DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. , 2010, Free radical biology & medicine.

[16]  A. Klančnik,et al.  Evaluation of diffusion and dilution methods to determine the antibacterial activity of plant extracts. , 2010, Journal of microbiological methods.

[17]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[18]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[19]  C. Schnell,et al.  PI3K inhibitors for cancer treatment: where do we stand? , 2009, Biochemical Society transactions.

[20]  D. Hallahan,et al.  DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs , 2005 .

[21]  W. Tsai,et al.  Evaluation of caffeic acid amide analogues as anti-platelet aggregation and anti-oxidative agents. , 2005, Bioorganic & medicinal chemistry.

[22]  J. Schiro,et al.  DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. , 2003, Molecular cancer therapeutics.

[23]  David J. Chen,et al.  Requirement for the Kinase Activity of Human DNA-Dependent Protein Kinase Catalytic Subunit in DNA Strand Break Rejoining , 1999, Molecular and Cellular Biology.

[24]  S. Jackson,et al.  The DNA-dependent protein kinase , 1999 .

[25]  Y. Shiloh,et al.  ATM: from gene to function. , 1998, Human molecular genetics.

[26]  K. Rosenzweig,et al.  Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  S. Boulton,et al.  Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. , 1996, Carcinogenesis.

[28]  B. Price,et al.  The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. , 1996, Cancer research.

[29]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[30]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[31]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[32]  N. Curtin,et al.  Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination , 2011, Cancer Chemotherapy and Pharmacology.